Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders
US9067997B2 · kind B2 · utility
20Cited by
1References
35Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 25, 2012 |
| Grant date | Jun 30, 2015 |
| Priority date | — |
| Expiry date | May 25, 2032 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to compounds that inhibit KIR2DL1, 2 and/or 3 polypeptide comprising compounds (e.g., anti-KIR2DL1, 2, and/or 3 antibodies) that neutralize NK cell inhibitory receptors and methods of using such compounds and compositions containing in the treatment and prevention of inflammatory or autoimmune disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.